IL133907A0 - Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor - Google Patents

Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Info

Publication number
IL133907A0
IL133907A0 IL13390798A IL13390798A IL133907A0 IL 133907 A0 IL133907 A0 IL 133907A0 IL 13390798 A IL13390798 A IL 13390798A IL 13390798 A IL13390798 A IL 13390798A IL 133907 A0 IL133907 A0 IL 133907A0
Authority
IL
Israel
Prior art keywords
glucocidase
thiazolidinedione
diabetes
inhibitor
alpha
Prior art date
Application number
IL13390798A
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL133907A0 publication Critical patent/IL133907A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL13390798A 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor IL133907A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Publications (1)

Publication Number Publication Date
IL133907A0 true IL133907A0 (en) 2001-04-30

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13390798A IL133907A0 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Country Status (27)

Country Link
EP (1) EP1001784A1 (en)
JP (1) JP2001510160A (en)
KR (1) KR20010021952A (en)
CN (1) CN1263467A (en)
AP (1) AP2000001735A0 (en)
AR (2) AR016350A1 (en)
AU (1) AU8449098A (en)
BG (1) BG104062A (en)
BR (1) BR9810292A (en)
CA (1) CA2297133A1 (en)
CO (1) CO4940489A1 (en)
DZ (1) DZ2563A1 (en)
EA (1) EA200000140A1 (en)
GB (1) GB9715298D0 (en)
HU (1) HUP0003626A3 (en)
ID (1) ID23804A (en)
IL (1) IL133907A0 (en)
MA (1) MA24608A1 (en)
NO (1) NO20000230D0 (en)
OA (1) OA11312A (en)
PE (1) PE99499A1 (en)
PL (1) PL338140A1 (en)
SK (1) SK612000A3 (en)
TR (1) TR200000133T2 (en)
UY (1) UY25101A1 (en)
WO (1) WO1999003478A1 (en)
ZA (1) ZA986364B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE372782T1 (en) 1999-06-21 2007-09-15 Lilly Co Eli SYNERGITIC USE OF THIAZOLIDINEDIONES AND GLUCAGONE-LIKE PEPTIDE-1 AND THEIR AGONISTS FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES
JP2003520226A (en) * 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト Combination comprising a dipeptidyl peptidase-IV inhibitor and an antidiabetic agent
WO2001062295A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Drugs containing combined active ingredients
JP4917712B2 (en) * 2000-02-24 2012-04-18 武田薬品工業株式会社 Concomitant medication
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
CN101103993B (en) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 Hypoglycemic medicine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101866T3 (en) * 1991-08-26 1997-07-16 Upjohn Co LIQUID FOOD PRODUCT CONTAINING 3-GUANIDINOPROPIONIC ACID.
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
EA200000140A1 (en) 2000-06-26
CN1263467A (en) 2000-08-16
TR200000133T2 (en) 2000-09-21
SK612000A3 (en) 2000-07-11
JP2001510160A (en) 2001-07-31
AP2000001735A0 (en) 2000-01-16
DZ2563A1 (en) 2003-02-15
UY25101A1 (en) 2000-12-29
KR20010021952A (en) 2001-03-15
ZA986364B (en) 2000-01-17
CO4940489A1 (en) 2000-07-24
WO1999003478A1 (en) 1999-01-28
CA2297133A1 (en) 1999-01-28
NO20000230L (en) 2000-01-17
EP1001784A1 (en) 2000-05-24
NO20000230D0 (en) 2000-01-17
HUP0003626A2 (en) 2001-05-28
AR019724A2 (en) 2002-03-13
PL338140A1 (en) 2000-09-25
PE99499A1 (en) 1999-12-18
AU8449098A (en) 1999-02-10
BG104062A (en) 2000-11-30
MA24608A1 (en) 1999-04-01
BR9810292A (en) 2000-09-19
ID23804A (en) 2000-05-11
HUP0003626A3 (en) 2001-12-28
AR016350A1 (en) 2001-07-04
GB9715298D0 (en) 1997-09-24
OA11312A (en) 2003-10-24

Similar Documents

Publication Publication Date Title
AP9901719A0 (en) Treatment of diabetes with thiazolidinedione and metormin
HK1045111A1 (en) (3-Trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin reisistance and type 2 diabetes
IL131130A0 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
PL342517A1 (en) Methods of treating diabetes employing peptidic insulin analoques
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
IL127219A0 (en) The use of insulin sensitivity enhancers for treatment of hyperuricemia and compositions containing insulin sensitivity enhancers for treating the same
IL134046A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
EG21712A (en) Treatment of insulin resistance
ZA98647B (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
PL343123A1 (en) Treatment of diabetes with rosiglitazone and insulin
IL133907A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
IL134045A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL133137A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL133138A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL121656A0 (en) Diagnosis prevention and treatment of diabetes